HUTCHMED (China) Limited (FRA:H7T2)

Market Cap	2.17B -3.0%
Revenue (ttm)	512.77M -1.4%
Net Income	397.55M
EPS	0.45
Shares Out	n/a
PE Ratio	5.45
Forward PE	11.50
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	9
Open	2.360
Previous Close	2.360
Day's Range	2.360 - 2.360
52-Week Range	2.060 - 3.160
Beta	n/a
RSI	49.91
Earnings Date	Mar 5, 2026

About HUTCHMED (China)

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. The company offers Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), ...

• Industry: Pharmaceutical Preparations
• Founded: 2000
• Employees: 1,780
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: H7T2

Financial Performance

In 2024, HUTCHMED (China)'s revenue was $630.20 million, a decrease of -24.80% compared to the previous year's $838.00 million. Earnings were $37.73 million, a decrease of -62.56%.

Financial numbers in USD